Which company can turn new advances in molecular genetics into money the fastest?
News & Analysis: Guardant Health
Thrive, a new liquid biopsy start-up, emerged from stealth by raising over $110 million in private capital.
Investors aiming to buy into the next big thing may want to take a look at these stocks. But beware: Sometimes the market already expects great things.
It's a leader in an early-stage area with massive growth potential.
These stocks are leading the way in their respective areas in battling cancer.
The liquid biopsy pioneer announced strong operating results from the first three months of the year.
If you're looking to level up, these stocks could be just what you need.
Here's how they could continue to climb.
They're leaders in their markets. And those markets should grow tremendously.
Roku, Guardant Health, and Carvana have all soared to start the year. Should the buyer beware or let the good times roll?